• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Background:
To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent.
Methods:
A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia, schizophreniform disorder, or schizoaffective disorder compared white (N=605) and black (N=375) patients treated with olanzapine (5 to 20 mg/day) for 24 to 28 weeks. Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total score; and positive, negative, and general psychopathology scores; and the Clinical Global Impression of Severity (CGI-S) scores at 6 months. Safety measures included differences in the frequencies of adverse events along with measures of extrapyramidal symptoms, weight, glucose, and lipid changes over time.
Results:
51% of black patients and 45% of white patients experienced early study discontinuation (P=.133). Of those who discontinued, significantly more white patients experienced psychiatric worsening (P=.002) while significantly more black patients discontinued for reasons other than efficacy or tolerability (P=.014). Discontinuation for intolerability was not different between groups (P=.320). For the estimated change in PANSS total score over 6 months, there was no significant difference in efficacy between white and black patients (P=.928), nor on the estimated PANSS positive (P=.435), negative (P=.756) or general psychopathology (P=.165) scores. Overall, there was no significant difference in the change in CGI-S score between groups from baseline to endpoint (P=.979). Weight change was not significantly different in white and black patients over 6 months (P=.127). However, mean weight change was significantly greater in black versus white patients at Weeks 12 and 20 only (P=.028 and P=.026, respectively). Additionally, a significantly greater percentage of black patients experienced clinically significant weight gain ([greater than or equal to]7%) at anytime compared to white patients (36.1% vs. 30.4%, P=.021). Changes across metabolic parameters (combined fasting and random lipids and glucose) were also not significantly different between groups, with the exception of a greater categorical change in total cholesterol from borderline to high among white subjects and a categorical change from normal to low in high density lipoprotein (HDL) cholesterol among white males.
Conclusions:
The findings did not demonstrate overall substantive differences in efficacy or safety between white and black patients diagnosed with schizophrenia or related disorders treated with olanzapine. However, a significantly greater percentage of black patients (36.1%) experienced clinically significant weight gain compared to white patients (30.4%).

Posted in: Open Access Journal Articles on 11/03/2010 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2025 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice